Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML

Feven Tameire(FuelCell Energy (United States)), Nandita Bose(FuelCell Energy (United States)), Ben J. Harrison(The University of Melbourne), Paulina M. Wojnarowicz(Memorial Sloan Kettering Cancer Center), Michael E. Stokes(Ithaka Harbors), Nicholas Collette(FuelCell Energy (United States)), Kathryn Bieging-Rolett(Stanford University), Ashley LaCayo(FuelCell Energy (United States)), David Surguladze(Intellicell Biosciences (United States)), Kirk A. Staschke(Indiana University School of Medicine), Jeremy Drees(FuelCell Energy (United States)), Eric S. Lightcap(Minneapolis Business College), Sho Fujisawaa(FuelCell Energy (United States)), Crissy Dudgeon(Rutgers, The State University of New Jersey)
Blood
November 2, 2023
Cited by 3


Related Papers